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Measurement of plasma leptin levels
Blood samples (5 ml) were collected and centrifuged at 2,000 rpm for 10 minutes. The plasma was stored in aliquots at -80°C for leptin measurements. Samples were magnetically labeled using a human, magnetic, premixed, microparticle cocktail of antibodies (Kit Lot Number L120614). 50μL of the microparticle cocktail and 50μL of the standard or sample were added to each well of a microplate. Plates were then placed on a horizontal orbital microplate shaker set at 800 ± 50 rpm. After washing, 50μL of a diluted biotin-antibody cocktail was added to each well and the plates were incubated. After washing, 50μL diluted Streptavidin-PE was added to each well, and the plates were incubated. After washing, the microparticles were suspended by adding 100μL of wash buﬀer to each well. The plates were then incubated for 2 minutes on the shaker set at 800 ± 50rpm. The final sample was read within 90 minutes using a Luminex MAGPIX technology (SN, USA). Duplicate readings for each standard and sample were averaged, and the average blank Median Fluorescence Intensity (MFI) was subtracted. A standard curve was generated for each cytokine to convert the MFI into the corresponding leptin relative concentration. The sensitivity of the assay for leptin was 104.940 pg/ml (minimum detectable level). After obtaining the blood samples, all subjects underwent MRI within 24 hours.
HAMD factor analyses
We used AMOS 17.0 (SPSS Inc., Chicago, IL, USA) for CFA analyses. CFA by max likelihood method was used to ascertain the factor structure of HAMD. Several model fit indices were used to evaluate the goodness-of-fit of the model with the given dataset: the goodness of fit index (GFI), the normal fit index (NFI), Tucker-Lewis Index (TLI), the incremental fit index (IFI), the comparative fit index (CFI), the standardized root mean square residual (SRMR), and the root mean square error of approximation (RMSEA). The GFI, NFI, TLI, IFI, and CFI values above 0.90, and SRMR values below 0.08 are considered acceptable. Regarding the RMSEA, a value ≤ 0.10 indicates good model fit.
Statistical analyses
Demographic and clinical characteristic analyses
Analyses of demographic and clinical characteristics and plasma leptin levels were performed using analysis of covariance (ANCOVA) and chi-square tests in the SPSS statistics software. Statistical significance was determined by P < 0.05.
ReHo alterations across diagnostic groups
We have performed additional analyses to compare ReHo values showing significant differences between MPDs and healthy controls in SCZ vs. HC, BPD vs. HC, and MDD vs. HC. Statistical significance was defined as P < 0.05, Bonferroni corrected for multiple comparisons.
Effects of illness duration on ReHo values and leptin levels
Nonparametric Spearman’s correlation analyses (two-tailed) were performed to determine the relationship between illness duration and ReHo values that showed significant group differences as well as leptin in patients with MPDs. Statistical significance was set at P < 0.05, false discovery rate (FDR) corrected for multiple comparisons.
Effects of the first episode and medication status on ReHo values and leptin levels
We subdivided the patient group into two subgroups according to their clinical information: first-episode vs. relapsed subgroups and medicated vs. nonmedicated subgroups for the ReHo values and leptin levels. Then, two-sample t-tests were performed between each pair of subgroups. Statistical significance was determined using FDR-corrected P < 0.05.
Mediation analyses across diagnostic groups
Mediation analysis within each diagnostic group was performed using PROCESS for SPSS 22.0 with a 5000 bootstrap samples. Age, gender, mean FD and medication as covariates were served as the covariates in mediation analyses. Statistical significance was achieved when 95% confidence intervals (CI) did not include zero for the estimates of indirect effect.

Supplementary Results
Demographic and clinical characteristic analyses
The variation within each group of data was checked before the statistical analyses. No significant differences in age, gender, handedness, BMI and smoking among the SCZ, BPD, MDD, and healthy controls were observed. Detailed demographic and clinical characteristics of major depressive disorder (MDD), bipolar disorder (BPD), and schizophrenia (SCZ) groups are shown in Table S1.
HAMD factor analyses
The model fit indices were as follows: GFI = 0.934, NFI = 0.935, TLI = 0.944, IFI = 0.953, CFI = 0.953, AGFI = 0.911, SRMR = 0.033, and RMSEA = 0.060. CFA results indicated that this model had a good fit.
Analyses of plasma leptin levels
Comparing each patient group to healthy controls, post-hoc analysis showed that plasma leptin levels were higher in MDD, BPD, and SCZ groups. Specific leptin levels of the MDD, BPD, and SCZ groups are listed in Figure S2 and Table S1.
ReHo value findings
The SCZ, BPD, and MDD groups shared ReHo alterations in 86% of the total regions with significant four-group differences. Overlap regions included left primary somatosensory cortex, left primary auditory cortex, right primary visual cortex, bilateral orbital frontal cortices, bilateral dorsolateral prefrontal cortices, and right angular gyrus. Additionally, the SCZ and BPD groups, but not the MDD group, had three clusters of significant ReHo alternations when compared with HC. These clusters consisted of right primary somatosensory cortex, left visual association cortex, and left angular gyrus. Significant ReHo reduction in the right visual association cortex was observed in the SCZ group only when compared with HC. No significant differences in ReHo values were observed between the MDD and controls in any of the four clusters (Figure S1).
Effects of illness duration on ReHo values and leptin levels
Illness duration was significantly negatively correlated with ReHo values in the right primary somatosensory cortex ( r = -0.017, P = 0.031) and left visual association cortex( r = -0.168, P = 0.002), and was significantly positively correlated with ReHo values in the left angular gyrus ( r = 0.136, P = 0.012) in patients with MPDs (Table S8).
Effects of the first episode and medication status on ReHo values and leptin levels
No significant differences were observed for ReHo values and leptin levels, either between the first-episode and relapsed subgroups or between the medicated and nonmedicated subgroups (Table S8).
Mediation analyses across diagnostic groups







Figure S1. Cluster-based post hoc analyses in regional homogeneity values in patients with schizophrenia, bipolar disorder, major depressive disorder and healthy controls.
* Statistical significance was determined by Bonferroni-corrected P < 0.05. 
BPD = bipolar disorder; HC = healthy controls; MDD= major depressive disorder; SCZ = schizophrenia
 
Figure S2. Group differences in plasma leptin levels in patients with schizophrenia, bipolar disorder, major depressive disorder and healthy controls.
*, Statistical significance was determined by Bonferroni-corrected P < 0.05. 







Table S1. Demographic and clinical characteristics in patients with major psychiatric disorders.
Characteristic	Group; mean ± SD or no. (%)		
	Control (n = 325)	MDD (n = 153)	BPD (n = 123)	SCZ (n = 127)	Statistics	P value
Demographic characteristic	
Age, years	29.24 (9.94)	29.87 (8.90)	28.11(8.56)	27.13 (8.99)	2.488	0.059
Gender (male/female)	132/193	44/109	51/72	48/79	7.120	0.068
Right handedness	303 (93%)	135 (88%)	119 (97%)	106 (83%)	11.174	0.083
Weight1	62.41 (14.39)	59.73 (11.60)	65.09 (13.35)	64.48 (13.35)	4.315	0.005
BMI (kg/m2) 1	23.76 (26.60)	21.77 (3.65)	22.89 (3.91)	23.23 (4.04)	0.404	0.751
Smoking	37/188 (20%)	19/75 (25%)	19/67 (28%)	11/64 (17%)	3.530	0.317
Clinical characteristic
First episode, yes	-	125 (82%)	58 (47%)	79 (62%)	-	-
Medication, yes	-	83 (54%)	86 (70%)	90 (71%)	-	-
Antidepressant	-	71 (17%)	41 (10%)	13 (3%)	-	-
Mood stabilizer	-	1 (0.2%)	63 (16%)	6 (1%)	-	-
Antipsychotic	-	9 (2%)	46 (11%)	69 (17%)	-	-
Duration, months	-	22.12 (33.68)	48.46 (65.73)	30.44 (42.00)	-	-
HAMD2	1.27 (2.16)	20.07 (9.84)	11.54 (10.14)	7.15 (6.10)	260.998	< 0.001
YMRS3	0.25 (0.93)	1.20 (3.15)	5.89 (8.97)	1.71 (4.23)	46.076	< 0.001
BPRS4	18.42 (1.94)	26.70 (7.21)	25.57 (8.46)	32.85 (11.67)	112.986	< 0.001
Leptin (pg/ml) 5	5463.13 (4055.93)	6033.64 (5243.52)	9570.49 (8877.02)	14510.21 (12885.72)	12.299	< 0.001
Leptin (log) 5	3.57 (0.44)	3.61 (0.43)	3.81 (0.44)	3.97 (0.46)	7.19	< 0.001
BMI = Body Mass Index; BPD = bipolar disorder; BPRS = Brief Psychiatric Rating Scale; HAMD = Hamilton Depression Scale; MDD = major depressive disorder; SCZ = schizophrenia; YMRS = Young Mania Rating Scale.
1 Control, n = 314; MDD, n = 143; BPD, n = 120; SCZ, n = 122.
2 Control, n = 303; MDD, n = 150; BPD, n = 120; SCZ, n = 104.
3Control, n = 298; MDD, n = 137; BPD, n = 118; SCZ, n = 82. 
4Control, n = 237; MDD, n = 101; BPD, n = 79; SCZ, n =123. 
5 Control, n = 83; MDD, n = 41; BPD, n = 42; SCZ, n = 28. 


Table S2. Factor loadings of the HAMD.

Items	Factor   Loadings 


















HAMD = Hamilton Depression Scale. 
Loadings in bold indicate the maximum loading of each item onto one of the four factors. 
Factor 1 = psychological depressive symptoms.
Factor 2 = somatic depressive symptoms. 
Factor 3 = insomnia








Right primary somatosensory cortex	0.047	0.414
Left primary somatosensory cortex	0.025	0.661
Left primary auditory cortex	0.017	0.766
Right primary visual cortex	0.060	0.290
Right visual association cortex	0.035	0.543
Left visual association cortex	-0.036	0.521
Right orbital frontal cortex	-0.001	0.992
Left orbital frontal cortex	0.013	0.816
Right dorsolateral prefrontal cortex	-0.055	0.338




BMI = Body Mass Index.




Table S4. Correlations between regional homogeneity values and HAMD scores in patients with major psychiatric disorders.
Brain region	HAMD total score	Psychological depressive symptoms	Somatic depressive symptoms	Insomnia	Mixed symptoms
	r 		P	r 	P 	r	P 	r	P 	r	P 
Right primary somatosensory cortex	0.096	0.065	0.129	0.010*	0.114	0.023*	0.134	0.007*	-0.004	0.929
Left primary somatosensory cortex	0.084	0.109	0.100	0.046	0.135	0.007*	0.133	0.008*	0.021	0.678
Left primary auditory cortex	0.120	0.021*	0.103	0.040	0.124	0.013*	0.095	0.058	0.040	0.430
Right primary visual cortex	0.016	0.766	0.043	0.397	0.054	0.283	0.091	0.069	0.030	0.546
Right visual association cortex	0.072	0.167	0.115	0.022*	0.094	0.059	0.115	0.021*	0.017	0.738
Left visual association cortex	0.060	0.250	0.084	0.094	0.094	0.060	0.127	0.011*	0.012	0.804
Right orbital frontal cortex	-0.048	0.357	-0.073	0.146	-0.115	0.022*	-0.071	0.158	0.014	0.786
Left orbital frontal cortex	-0.038	0.471	-0.065	0.198	-0.082	0.100	-0.080	0.111	0.046	0.358
Right dorsolateral prefrontal cortex	-0.020	0.700	0.012	0.808	-0.044	0.379	-0.071	0.159	-0.043	0.388
Left dorsolateral prefrontal cortex	0.008	0.883	-0.013	0.799	-0.048	0.344	-0.080	0.110	-0.005	0.917
Right angular gyrus	0.013	0.803	0.012	0.812	-0.024	0.634	-0.025	0.618	0.012	0.814
Left angular gyrus	-0.040	0.440	-0.038	0.454	-0.101	0.045	-0.091	0.069	0.028	0.577
HAMD = Hamilton Depression Scale. 
*Correlation coefficients were statistically significant at P < 0.05 false discovery rate (FDR) corrected for multiple comparisons. Age, gender, mean framewise displacement (FD), and medication were treated as covariates.










HAMD = Hamilton Depression Scale.  
*Correlation coefficients were statistically significant at P < 0.05 false discovery rate (FDR) corrected for multiple comparisons. Age, gender, mean framewise displacement, and medication were treated as covariates.


Table S6. Correlations between regional homogeneity values and plasma leptin levels in patients with major psychiatric disorders.
Brain region	Leptin
	r	P 
Right primary somatosensory cortex	-0.245	0.011*
Left primary somatosensory cortex	-0.180	0.063
Left primary auditory cortex	-0.192	0.047
Right primary visual cortex	0.200	0.039
Right visual association cortex	-0.270	0.005*
Left visual association cortex	-0.306	0.001*
Right orbital frontal cortex	0.101	0.299
Left orbital frontal cortex	0.176	0.070
Right dorsolateral prefrontal cortex	0.077	0.431
Left dorsolateral prefrontal cortex	0.233	0.016*
Right angular gyrus	0.063	0.517
Left angular gyrus	-0.032	0.745








Table S7. Correlations between regional homogeneity values, plasma leptin levels, HAMD scores, and BMI in patients with major psychiatric disorders.
Brain region	BMI
	r	P 
Right primary somatosensory cortex	-0.145	0.005*
Left primary somatosensory cortex	-0.137	0.007*
Left primary auditory cortex	-0.207	0.000*
Right primary visual cortex	-0.139	0.007*
Right visual association cortex	-0.193	0.000*
Left visual association cortex	-0.181	0.000*
Right orbital frontal cortex	0.150	0.003*
Left orbital frontal cortex	0.124	0.016*
Right dorsolateral prefrontal cortex	0.153	0.003*




HAMD total score	-0.210	< 0.001*
Psychological depressive symptoms	-0.184	< 0.001*
Somatic depressive symptoms	-0.194	< 0.001*
Insomnia	-0.188	< 0.001*
Mixed symptoms	-0.122	0.017*
BMI = Body Mass Index.






Table S8. Effects of illness duration, first episode, medication status on regional homogeneity values and leptin levels in major psychiatric disorders.
Variables	Duration(months)	first episode (yes vs. no)	medication (on / off) 
	r	P	T	P	T	P
Right primary somatosensory cortex	-0.117	0.031*	-2.317	0.021	1.288	0.198
Left primary somatosensory cortex	-0.064	0.239	-0.805	0.421	.755	0.451
Left primary auditory cortex	-0.104	0.054	-1.987	0.048	1.735	0.084
Right primary visual cortex	-0.008	0.876	0.293	0.770	1.587	0.113
Right visual association cortex	-0.059	0.281	-0.339	0.735	1.712	0.088
Left visual association cortex	-0.168	0.002*	-2.688	0.007	0.940	0.348
Right orbital frontal cortex	0.108	0.045	2.858	0.004	0.114	0.909
Left orbital frontal cortex	0.035	0.516	1.802	0.072	1.612	0.108
Right dorsolateral prefrontal cortex	0.096	0.077	0.485	0.628	-1.574	0.116








Table S9. Mediation analysis of the relationship between regional homogeneity values and HAMD score, leptin as mediator.
Model	Effect type (mediator variable: leptin)	Point estimate*	SE	95% CI
A	Outcome variable: psychological depressive symptoms			
	Mediation effect (ReHo in right primary somatosensory cortex-leptin-psychological depressive symptoms)	2.032	1.018	0.535, 4.697
	Direct effect (ReHo in right primary somatosensory cortex-psychological depressive symptoms)	7.553	4.794	-1.978, 17.055
	Total effect	9.156	4.803	-0.363, 18.675
B	Outcome variable: psychological depressive symptoms			
	Mediation effect (ReHo in right visual association cortex-leptin-psychological depressive symptoms)	2.152	1.170	0.419, 5.590
	Direct effect (ReHo in right visual association cortex-psychological depressive symptoms)	7.874	4.411	-0.869, 16.617
	Total effect	10.062	4.027	2.081, 18.043
C	Outcome variable: somatic depressive symptoms			
	Mediation effect (ReHo in right primary somatosensory cortex-leptin-somatic depressive symptoms)	1.098	0.487	0.340, 2.309
	Direct effect (ReHo in right primary somatosensory cortex -depressive symptoms)	3.930	2.397	-0.821, 8.681
	Total effect	4.796	2.388	0.633, 9.528
ReHo = regional homogeneity. 95% CI, confidence interval of the point estimate.
*Point estimate, estimate of the size of the effect. Statistical significance was achieved when 95% confidence intervals (CI) did not include zero for the estimates of indirect effect. Models were adjusted for age, gender, mean framewise displacement, and medication. 


Table S10. Mediation Results in patients with major psychiatric disorders.

X-M-Y	Path A	Path B	Path C	Path C’	Path AB
Right visual association cortex-leptin- psychological depressive symptoms	−38242.653,−2912.998	−0.0002, 0.000	2.081, 18.043	−0.869, 16.617	0.419, 5.590
Right primary somatosensory cortex-leptin- somatic depressive symptoms	−31975.787, −3903.892	−0.0001, 0.000	0.063, 9.528	−0.821, 8.681	0.340, 2.309
Right primary somatosensory cortex- leptin-BMI	−31975.787, −3903.892	0.0002, 0.0003	−14.761, −2.048	−10.092, 0.092	−8.546, −1.305
Right visual association corte-leptin-BMI	−38242.653, −2912.998	0.0002,0.0003	−18.299, −4.879	−11.687, −1.882	−9.197, −0.835
left visual association cortex-leptin-BMI	−45302.334, −9777.606	0.0002, 0.0003	−21.544, −6.692	−14.264, −2.371	−11.567, −2.595
X-M-Y denotes the relationship among the independent variable (X), mediator (M), and dependent variable (Y). 










Table S11. Mediation analysis of the relationship between regional homogeneity values and BMI, leptin as mediator.
Model	Effect type (mediator variable: leptin)	Point estimate*	SE	95% CI
A	Outcome variable: BMI			
	Mediation effect (ReHo in right primary somatosensory cortex-leptin-BMI)	-4.318	1.796	-8.546, -1.305
	Direct effect (ReHo in right primary somatosensory cortex-BMI)	-5.000	2.569	-10.092, 0.092
	Total effect	-8.404	3.207	-14.761, -2.048
B	Outcome variable: BMI			
	Mediation effect (ReHo in right visual association cortex-leptin-BMI)	-4.726	2.105	-9.197, -0.835
	Direct effect (ReHo in right visual association cortex-BMI)	-6.784	2.473	-11.687, -1.882
	Total effect	-11.589	3.386	-18.299, -4.879
C	Outcome variable: BMI			
	Mediation effect (ReHo in left visual association cortex -leptin-BMI)	-6.318	2.203	-11.567, -2.945
	Direct effect (ReHo in left visual association cortex-BMI)	-8.318	3.000	-14.264, -2.371
	Total effect	-14.118	3.747	-21.544, -6.692
D	Outcome variable: BMI			
	Mediation effect (ReHo in left dorsolateral prefrontal cortex-leptin-BMI)	4.222	3.823	-2.460, 12.596
	Direct effect (ReHo in left dorsolateral prefrontal cortex-BMI)	8.212	4.212	-0.140, 16.565
	Total effect	16.566	6.476	3.756, 29.406
ReHo = regional homogeneity. 95% CI, confidence interval of the point estimate.
*Point estimate, estimate of the size of the effect. Statistical significance was achieved when 95% confidence intervals (CI) did not include zero for the estimates of indirect effect. Models were adjusted for age, gender, mean framewise displacement, and medication. 
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